Analyst Price Targets — AVTE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 17, 2024 4:07 pm | Liisa Bayko | Evercore ISI | $2.00 | $1.65 | TheFly | Aerovate Therapeutics downgraded to In Line from Outperform at Evercore ISI |
| June 17, 2024 12:15 pm | Eun Yang | Jefferies | $2.00 | $1.65 | StreetInsider | Jefferies Downgrades Aerovate Therapeutics Inc (AVTE) to Hold |
| April 1, 2024 5:54 am | Tiago Fauth | Wells Fargo | $35.00 | $29.57 | StreetInsider | Wells Fargo Adds Aerovate Therapeutics Inc (AVTE) to Q2 '24 Tactical Ideas List |
| March 25, 2024 7:56 am | Eun Yang | Jefferies | $65.00 | $26.95 | StreetInsider | Aerovate Therapeutics Inc (AVTE) PT Raised to $65 at Jefferies, 'valuation does not suggest data needs to be better than sotatercept' |
Latest News for AVTE
Aerovate Therapeutics (NASDAQ:AVTE) & AEON Biopharma (NASDAQ:AEON) Head to Head Survey
Aerovate Therapeutics (NASDAQ: AVTE - Get Free Report) and AEON Biopharma (NASDAQ: AEON - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings. Analyst Recommendations This is a breakdown of
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AVTE.
U.S. House Trading
No House trades found for AVTE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.